4278-08-4|2-(4-Fluorophenyl)-1H-imidazole| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 4278-08-4 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 4278-08-4 ]

CAS No. :	4278-08-4
Formula :	C₉H₇FN₂
M.W :	162.16
SMILES Code :	FC1=CC=C(C2=NC=CN2)C=C1
MDL No. :	MFCD04114652
InChI Key :	GTIYLLQEFVPNTN-UHFFFAOYSA-N
Pubchem ID :	11744944

Safety of [ 4278-08-4 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H319
Precautionary Statements:	P305+P351+P338

Computational Chemistry of [ 4278-08-4 ] Show Less

Physicochemical Properties

Num. heavy atoms	12
Num. arom. heavy atoms	11
Fraction Csp3	0.0
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	43.98
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	28.68 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.46
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.82
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.64
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.75
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.0
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.13

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.6
Solubility	0.403 mg/ml ; 0.00249 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.04
Solubility	1.47 mg/ml ; 0.00908 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.02
Solubility	0.0155 mg/ml ; 0.0000953 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.0 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.35

Application In Synthesis of [ 4278-08-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 4278-08-4 ]

[ 4278-08-4 ] Synthesis Path-Downstream 1~35

1
[ 4278-08-4 ]
[ 72542-80-4 ]

References: [1]Journal of Heterocyclic Chemistry,1979,vol. 16,p. 1153 - 1155.

2
[ 165901-26-8 ]
[ 4278-08-4 ]

Yield	Reaction Conditions	Operation in experiment
56.5%	With [bis(acetoxy)iodo]benzene; potassium carbonate; In dimethyl sulfoxide;Darkness;	To a solution of 2-aryl-4,5- dihydro-lH-imidazole 14b, x (35 mmol) in DMSO (100 mL) was added potassium carbonate (38.5 mmol) and diacetoxyiodobenzene (38.5 mmol). The reaction mixture was stirred overnight in darkness. Water was added followed by extraction with dichloromethane. The organic layer was dried over magnesium sulfate and concentrated. The residue was subjected to flash column chromatography (hexane: ethyl acetate 3:2) to give a white solid. Yield: 30%-50%.
56.5%	With [bis(acetoxy)iodo]benzene; potassium carbonate; In dimethyl sulfoxide;Darkness;	[002211 Method A (essential for only 9b, 9x, Figure 8): To a solution of 2-aryl-4,5- dihydro-1H-imidazole 14b, x (35 mmol) in DMSO (100 mL) was added potassium carbonate (38.5 mmol) and diacetoxyiodobenzene (38.5 mmol). The reaction mixture was stuffed overnight in darkness. Water was added followed by extraction with dichloromethane. The organic layer5 was dried over magnesium sulfate and concentrated. The residue was subjected to flash column chromatography (hexane: ethyl acetate 3:2) to give a white solid. Yield: 30%-50%.

References: [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 7414 - 7427.
[2]Patent: WO2011/109059,2011,A1 .Location in patent: Paragraph 0040; 00354.
[3]Patent: WO2014/138279,2014,A1 .Location in patent: Paragraph 00221; 00246.
[4]Journal of the American Chemical Society,2016,vol. 138,p. 7820 - 7823.
[5]Heterocycles,1995,vol. 40,p. 841 - 850.

4
7-[chloro(1-methyl-1H-imidazol-5-yl)methyl]-5-(3-chlorophenyl)tetrazolo[1,5-a]quinazoline monohydrochloride [ No CAS ]
[ 4278-08-4 ]
ClC₆H₄C₈H₃N₅CH(C₃H₂N₂)2CH₃C₆H₄F [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2007,vol. 42,p. 702 - 714.

5
[ 98-09-9 ]
[ 4278-08-4 ]
[ 1253697-41-4 ]

References: [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 7414 - 7427.

6
[ 1313517-69-9 ]
[ 4278-08-4 ]
[ 1313519-13-9 ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate;tris-(dibenzylideneacetone)dipalladium(0); 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 140℃; for 1.0h;microwave irradiation; Inert atmosphere;	Intermediate CC (1 10 mg, 0.363 mmol), 2-(4-fluorophenyl)-lH-imidazole (70 mg, 0.435 mmol), Pd2(dba)3 CHCl3 (166 mg, 0.182 mmol), BINAP (226 mg, 0.3638 mmol), and CS2CO3 (354 mg, 1.08 mmol) were dissolved in 1 mL of toluene in a microwave vial and a stream of nitrogen was bubbled through the mixture for 2 minutes. The resulting solution was heated at 140 C for 1 h in a microwave. The reaction mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate solution. The organic extracts were dried with Na2S04, filtered and evaporated, and the residue was purified by preparative HPLC to give the title compound (48 mg). LCMS: 429.1 m/z (M+H)+; ret. Time 3.23 min (Analytical Method A).

References: [1]Patent: WO2011/79114,2011,A1 .Location in patent: Page/Page column 157.

7
[ 1313518-05-6 ]
[ 4278-08-4 ]
[ 1313519-31-1 ]

Yield	Reaction Conditions	Operation in experiment
	In dimethyl sulfoxide; at 120℃; for 2.0h;	To a stirring mixture of Intermediate RR-1 (112 mg, 0.338 mmol) in 0.7 mL of DMSO, 2-(4-fluorophenyl)-lH-imidazole (109 mg, 0.67 mmol) was added. The reaction mixture was placed in a 120 C oil bath for 2 h. The crude mixture was directly loaded and purified by silica gel chromatography to give the coupled nitro ester. LCMS: 457.1 m/z (M+H)+. To a stirring mixture of the coupled nitro ester in 1.2 mL of MeOH, Pt/C (42 mg) was added and the reaction mixture was placed under 1 atm of hydrogen for 2 h. The hydrogen balloon was removed and VO(acac)2 (5 mg) was added. This reaction mixture was placed under 1 atm of hydrogen overnight. The crude mixture was filtered through a plug of Celite and the plug was washed several times with EtOAc. The filtrate was concentrated under reduced pressure. To this cyclized product, 0.5 mL of dioxane, potassium bicarbonate (100 mg) and trimethylphosphate (200 mg) were added. The reaction mixture was warmed to 100 C for several hours. The crude product mixture was cooled to rt and diluted with EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc. The organic layers were dried over MgS04, filtered, and concentrated under reduced pressure. The resulting material was purified by preparative HPLC to give the title compound. LCMS: 409.1 m/z (M+H)+; ret. Time 4.07 min (Analytical MethodD).

References: [1]Patent: WO2011/79114,2011,A1 .Location in patent: Page/Page column 167.

8
[ 1313518-05-6 ]
[ 4278-08-4 ]
[ 1313519-32-2 ]

References: [1]Patent: WO2011/79114,2011,A1 .

9
[ 1445-45-0 ]
[ 1313518-05-6 ]
[ 4278-08-4 ]
[ 1371625-19-2 ]

Yield	Reaction Conditions	Operation in experiment
		To a stirring mixture of Intermediate R -1 (0.338 mmol) in DMSO, 2-(4- fluorophenyl)-lH-imidazole (0.67 mmol) is added. The reaction mixture is placed in a 120 C oil bath for 2 h. The crude mixture is directly loaded and purified by silica gel chromatography to give the coupled nitro ester. To a stirring mixture of the coupled nitro ester in MeOH, Pt/C (42 mg) is added and the reaction mixture is placed under 1 atm of hydrogen for 2 h. The hydrogen balloon is removed and VO(acac)2 is added. This reaction mixture is placed under 1 atm of hydrogen overnight. The crude mixture is filtered through a plug of Celite and the plug is washed several times with EtOAc. The filtrate is concentrated under reduced pressure. This cyclized compound is then reacted similarly to the final step of Example 13 with either trimethyl ortho formate or trimethylorthoacetate to give the title compounds.

References: [1]Patent: WO2012/48129,2012,A2 .Location in patent: Page/Page column 368.

10
[ 1313518-05-6 ]
[ 4278-08-4 ]
[ 149-73-5 ]
[ 1371625-18-1 ]

Yield	Reaction Conditions	Operation in experiment
		To a stirring mixture of Intermediate R -1 (0.338 mmol) in DMSO, 2-(4- fluorophenyl)-lH-imidazole (0.67 mmol) is added. The reaction mixture is placed in a 120 C oil bath for 2 h. The crude mixture is directly loaded and purified by silica gel chromatography to give the coupled nitro ester. To a stirring mixture of the coupled nitro ester in MeOH, Pt/C (42 mg) is added and the reaction mixture is placed under 1 atm of hydrogen for 2 h. The hydrogen balloon is removed and VO(acac)2 is added. This reaction mixture is placed under 1 atm of hydrogen overnight. The crude mixture is filtered through a plug of Celite and the plug is washed several times with EtOAc. The filtrate is concentrated under reduced pressure. This cyclized compound is then reacted similarly to the final step of Example 13 with either trimethyl ortho formate or trimethylorthoacetate to give the title compounds.

References: [1]Patent: WO2012/48129,2012,A2 .Location in patent: Page/Page column 368.

11
[ 459-57-4 ]
[ 4278-08-4 ]

References: [1]Patent: WO2014/138279,2014,A1 .
[2]Journal of the American Chemical Society,2016,vol. 138,p. 7820 - 7823.
[3]Patent: WO2011/109059,2011,A1 .

12
[ 1313517-71-3 ]
[ 4278-08-4 ]
[ 1313572-42-7 ]